Podcasts about Targeted therapy

Why has Lipoprotein(a) emerged as one of the hottest topics in preventive cardiology? In Part 2, Professor Devaki Nair explains when clinicians should measure Lipoprotein(a), how elevated levels influence cardiovascular risk, and how emerging targeted therapies could transform prevention strategies in the coming decade. Timestamps: 00:00 – 00:40: Introduction 00:40 – 03:03: Lipoprotein(a)'s Rise 03:03 – 04:58: Measuring Lipoprotein(a) 04:58 – 08:04: Cardiovascular Risk 08:04 – 10:04: Targeted Therapies 09:28 – 12:12: Patient Referral

Highlights from the PER® CME activity "OncoBytes Adaptive Learning Pathways™: Decoding Precision Diagnostics and Targeted Therapies in Glioma" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Vinay K. Puduvalli, MD; Ruham Nasany, MD; and Angela Waanders, MD, MPH, MS; discuss advances in molecular diagnostics and strategies to treat adults with low- and high-grade gliomas.Earn CME credit by completing the full accredited activity (available through September 1, 2027): https://www.gotoper.com/courses/oncobytes-adaptive-learning-pathways-decoding-precision-diagnostics-and-targeted-therapies-in-gliomaThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Highlights from the PER® CME activity "Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Joyce O'Shaughnessy, MD, Sarat Chandarlapaty, MD, PhD, Mitchell Elliott, MD, FRCPC, and Seth A. Wander, MD, PhD, discuss how they are integrating recent data from pivotal clinical trials evaluating next-generation oral selective estrogen receptor degraders (SERDs) as well as inhibitors of the PI3K/AKT/mTOR signaling pathway into the management of patients with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (mBC), using a variety challenging clinical scenarios to draw out insights and clinical pearls.Earn CME credit by completing the full accredited activity (available through July 31, 2027): https://www.gotoper.com/courses/advancing-targeted-therapy-in-hrher2-metastatic-breast-cancer-integrating-next-generation-endocrine-and-pam-pathway-strategies-into-practiceThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from Lilly; Rigel Pharmaceuticals; and Stemline Therapeutics, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

As part of the September issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief Editor James Chalmers interviews editorial board member Christina Thornton and associate editor Marcus Mall about their Back to Basics review article on bridging the airway microbiome and targeted therapy in bronchiectasis, published in this issue of the ERJ (https://doi.org/10.1183/13993003.00239-2026). Cite this podcast as: ERJ Podcast September 2026: The airway microbiome and targeted therapy in bronchiectasis. Eur Respir J 2026; 68: 26E6803 [https://doi.org/10.1183/13993003.E6803-2026].

Welcome to The Better Life with Dr. Pinkston! In this episode, Dr. Pinkston is joined by Steven McConnell—lipidemiologist, founder, and CSO of Health Defenders—for a deep dive into root-cause solutions for kidney disease, cardiovascular health, and integrative medicine. With over three decades of clinical background and research, Steven shares his inspiring personal journey and groundbreaking insights into reversing Chronic Kidney Disease (CKD) and Acute Kidney Injury (AKI). In this episode, Dr. Pinkston and Steven discuss: Root Causes of Kidney Disease: Why conventional staging with creatinine often misses early-stage disease and why testing Cystatin C and the Albumin-Creatinine Ratio (ACR) is critical. The Thyroid & Kidney Connection: How acidosis and hormone leakage impact kidney function and GFR. Cardiovascular & Lipid Links: The role of Lipoprotein(a) [Lp(a)], advanced lipid testing, and targeted interventions. Targeted Therapies & Inflammation: The benefits and proper use of Niacin, Colchicine, and blood pressure management tailored for kidney health. Actionable Protocols: Practical strategies for taking control of your health beyond conventional 12-minute doctor visits.See omnystudio.com/listener for privacy information.

In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Steven Kao, Medical Oncologist at Chris O'Brien Lifehouse, is joined by A/Prof Venessa Chin, Medical Oncologist at St Vincent's Hospital and Researcher at the Garvan Institute of Medical Research, and Dr Ben Kong, Medical Oncologist at Prince of Wales Hospital. Together, they explore the clinical features of ROS1-positive non-small cell lung cancer, the evolving diagnostic and treatment landscape in Australia, and how the recent PBS listing of repotrectinib is influencing first-line treatment decisions. The discussion also covers CNS disease, treatment sequencing, resistance mechanisms, and emerging therapies that may further improve outcomes for patients. This podcast was proudly sponsored by Bristol Myers Squibb. All development and editorial decisions were made independently by the speakers. (00:00) Introduction, Host Welcome & Acknowledgement of Country (01:33) The "Unicorn" Mutation: Clinical Characteristics & Prevalence (03:22) Diagnostic Testing: IHC, FISH vs. Gold Standard NGS (05:15) Clinical Red Flags: High Thromboembolic Risk & CNS Predilection (08:18) Treatment Landscape in Australia: Crizotinib, Entrectinib, Repotrectinib (10:11) Managing Unique Repotrectinib Side Effects (Dizziness, Dysgeusia, Ataxia) (13:42) Intracranial Response & Choosing First-Line TKIs (19:20) Post-TKI Progression Strategies: Biopsy, Chemo-IO, & Local Stereotactic Radiotherapy (SRS) (26:15) The Horizon: Emerging Next-Generation TKIs & Resected ROS1 Disease (29:05) Closing Remarks ---------------Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Please visit answersincme.com/SJN860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jewel M. Kling, MD, MPH and Genevieve Neal-Perry, MD, PhD. In this activity, experts in menopause management discuss unmet therapeutic needs, emerging evidence for neurokinin (NK) receptor antagonists, and patient-focused strategies for managing menopause-associated vasomotor symptoms (VMS). Upon completion of this activity, participants should be better able to: Recognize unmet therapeutic needs among patients with menopause-associated VMS; Assess the evidence for nonhormonal therapies targeting NK receptors in the treatment of menopause-associated VMS; and Formulate patient-focused strategies for the optimal use of NK receptor antagonists for menopause-associated VMS.

Highlights from the PER® CME activity "MET Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; and Anne S. Tsao, MD, MBA, discuss diagnostic and treatment strategies for patients with MET-altered non–small cell lung cancer.Earn CME credit by completing the full accredited activity (available through September 19, 2026): https://www.gotoper.com/courses/met-alterations-in-nsclc-applying-diagnostic-advances-and-targeted-therapies-in-a-new-era-of-treatment-vdpvThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from AbbVie, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss optimal care for patients with HR-positive/HER2-negative breast cancer receiving newer oral targeted therapies. Their conversation addresses treatment selection across early-stage and metastatic disease, biomarker-informed decision-making, adverse event management, and practical strategies to help patients remain on therapy. Key topics include: Selecting and sequencing oral targeted therapies, including CDK4/6 inhibitors, PARP inhibitors, PI3K/AKT pathway inhibitors, and oral SERDs Identifying patients with high-risk early breast cancer and applying evidence from trials such as monarchE, NATALEE, and OlympiA Using biomarkers such as BRCA1/2, PIK3CA, AKT1, PTEN, and ESR1 to guide therapy in metastatic disease Monitoring and managing treatment-related adverse events, including neutropenia, diarrhea, hepatotoxicity, QTc prolongation, hyperglycemia, rash, stomatitis, anemia, nausea, and fatigue Using dose modification, supportive care, patient education, and proactive follow-up to improve adherence and persistence with oral therapy Incorporating oncology pharmacists and the multidisciplinary care team into ongoing treatment monitoring and patient support PresentersDanielle Roman, PharmD, BCOP Manager, Oncology Clinical Pharmacy Services Oncology Clinical Pharmacy Specialist Allegheny Health Network Pittsburgh, Pennsylvania Jordan Hill, PharmD, BCOP Clinical Pharmacy Specialist, Breast Oncology West Virginia University Cancer Institute Morgantown, West Virginia Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Access the full educational program: Link to full program:https://bit.ly/4gvZerW And be sure to try our Interactive Decision Support Tools for Early Breast Cancer and Selecting AKT or PI3K Inhibitors for Patients With Metastatic Breast Cancer. By answering just a few quick questions, you can see what 5 experts would recommend for specific patient scenarios. Early Breast Cancer:https://bit.ly/4gtUiUq AKT or PI3K Inhibitors in MBC:https://bit.ly/4qcyBvk Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Since its FDA approval on March 26, 2025, cabozantinib has emerged as the newest treatment option for neuroendocrine tumors (NET) patients—adding another valuable tool to the treatment toolbox. It's become a hot topic in support groups and forums, with many patients wondering what to expect. In this episode, Fox Chase Cancer Center medical oncologist Dr. Namrata (“Neena”) Vijayvergia answers the most frequently asked questions about cabozantinib. She explains how it works, how it differs from other therapies, what patients should know about dosing and side effects, and shares insights on a new clinical trial exploring the next generation of cabozantinib.TOP TEN QUESTIONS1. What is cabozantinib? Is it considered chemotherapy? 2. How does cabozantinib work? What do we mean by “targeted therapies”?3. Who is cabozantinib typically recommended for? When in someone's NET journey do you consider starting it?4. Why might a patient take cabozantinib instead of other treatment options?Is this a “last resort” treatment option?  Does it limit future choices or “burn any bridges”?5. What are the most common side effects? Will I look like a cancer patient? Will my hair fall out? How might I feel while taking it—can most people keep working and doing their usual activities?                                              Do common side effects tend to develop or get worse over time, or pretty much stay the same?6. What should patients watch out for or monitor while taking this medication?7. What should patients know about dosing? Is there a preferred starting dose or an “optimal” dose? If I tolerate a lower dose, should I go to a higher dose? 8. What happens if cabozantinib doesn't work for me? What other treatments might be available?9. I've heard about a drug called “Zanza,” the STELLAR-311 trial. What is it, and how does it fit into the current treatment landscape?10. What practical tips or “tricks of the trade” do you share with patients who may start this medication?Bonus: What's on the horizon in NET research or treatment that you're most excited about?ABOUT THE SPEAKERNamrata (Neena) Vijayvergia, MD, FACP, is a GI medical oncologist, clinical trialist, and physician leader known for bringing science, collaboration, and heart to the care of patients with gastrointestinal and neuroendocrine cancers. She is Section Chief of Gastrointestinal Oncology at Fox Chase Cancer Center and an Associate Professor, where she leads a broad research program—from early-phase therapeutics to biomarker-driven strategies and patient-centered outcomes—supported by NIH, NCCN, industry partners, and foundations. Neena is a frequent speaker at national and international meetings, including ASCO, NANETS, ESMO, and SNMMI, and was recently honored with the 2025 Distinguished Clinical Award from NANETS. She helps set national standards through service on ASCO, NCCN, ENETS, NCI, and NANETS committees and guideline panels, chairs the NANETS Scientific Review Committee, and leads cooperative group efforts within ECOG-ACRIN. A dedicated mentor and advocate, she supports trainees and junior faculty through formal mentoring programs, advises patient advocacy organizations, and engages in community-focused efforts to make cancer care more inclusive and equitable. Recognized in the ASCO Leadership Development Program and as a “40 Under 40 in Cancer,” she brings a strategic yet people-first approach to clinical trial development—always driven by the belief that teamwork, curiosity, and compassion can move the field forward for patients and the teams who care for them.Visit https://www.ncf.net/podcast/54 for more resources. For more information, visit NCF.net. 

Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive disease that can cause chronic pain, joint dysfunction, reduced mobility, and significant impacts on quality of life, particularly in patients with diffuse disease. In this expert discussion, Dr William Tap and Dr Emanuela Palmerini explore the evolving management of TGCT, including the biologic role of the CSF1/CSF1R pathway, challenges in diagnosis and disease monitoring, and the importance of multidisciplinary, patient-centered care. They also discuss the growing role of CSF1R-targeted therapies, treatment selection, toxicity management, drug holidays, and practical approaches to optimizing long-term outcomes for patients living with TGCT.  Topics Covered Understanding localized vs diffuse TGCT Biology of the CSF1/CSF1R pathway Diagnostic approaches and the role of MRI and biopsy Multidisciplinary care and shared decision-making Impact of TGCT on function, mobility, and quality of life Current and emerging CSF1R-targeted therapies Pexidartinib and vimseltinib: clinical considerations and toxicity management Response assessment beyond imaging Drug holidays, retreatment strategies, and long-term follow-up Future directions in TGCT research and treatment Faculty William Tap, MD Emanuela Palmerini, MD, PhD Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Gilles Salles, MD, PhD, and Pier Luigi Zinzani, MD, PhD, discuss the role of new and emerging targeted therapies in the management of patients with DLBCL, including: Overview of Unmet Needs With Current Standard of Care in DLBCL Expanding Role of Novel Agents in DLBCL  Access to Targeted Therapies and Clinical Trials in Non-Academic DLBCL Practice  Key Ongoing Trials of new and novel agents in DLBCL  Key Presentations/Results at EHA 2026 in DLBCL Presenters:  Gilles Salles, MD, PhD Service Chief, Lymphoma Service Steven Greenberg Chair Memorial Sloan Kettering Cancer Center Weill Cornell University New York, New York Pier Luigi Zinzani, MD, PhD Professor of Hematology Alma Mater Studiorum-University of Bologna Head, “Seràgnoli” Institute of Hematology IRCCS Azienda Ospedaliero-Universitaria di Bologna Department of Medical and Surgical Sciences Bologna University School of Medicine Bologna, Italy Link to full program:https://bit.ly/4gmyoS7 Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Stephen V. Liu, MD, the division chief of Hematology Oncology at MedStar Georgetown University Hospital, part of the MedStar Georgetown Cancer Institute, in Washington, DC.Their discussion centered on the continued evolution of precision medicine in non–small cell lung cancer (NSCLC), highlighting advances in molecular testing, targeted therapies, immunotherapy, and emerging treatment strategies presented at the 2026 ASCO Annual Meeting. Drs Park and Liu explored how lung cancer has become a model for precision oncology and emphasized that therapeutic advances across multiple tumor types have collectively shaped the current treatment landscape. They discussed the importance of understanding oncogenic drivers, overcoming resistance mechanisms, and moving effective therapies into earlier-stage disease to improve long-term patient outcomes.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HMB865. CME/EBAH/NCPD/CPE/AAPA credit will be available until July 24, 2027.Mapping the Pathways to Long-Term Treatment Benefit in Chronic Lymphocytic Leukemia (CLL): Strategies for Aligning Patient Priorities With Evidence for Initiating & Sequencing Targeted Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HMB865. CME/EBAH/NCPD/CPE/AAPA credit will be available until July 24, 2027.Mapping the Pathways to Long-Term Treatment Benefit in Chronic Lymphocytic Leukemia (CLL): Strategies for Aligning Patient Priorities With Evidence for Initiating & Sequencing Targeted Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HMB865. CME/EBAH/NCPD/CPE/AAPA credit will be available until July 24, 2027.Mapping the Pathways to Long-Term Treatment Benefit in Chronic Lymphocytic Leukemia (CLL): Strategies for Aligning Patient Priorities With Evidence for Initiating & Sequencing Targeted Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HMB865. CME/EBAH/NCPD/CPE/AAPA credit will be available until July 24, 2027.Mapping the Pathways to Long-Term Treatment Benefit in Chronic Lymphocytic Leukemia (CLL): Strategies for Aligning Patient Priorities With Evidence for Initiating & Sequencing Targeted Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

Should you go natural or conventional? Dr. Pai explains how to combine treatments based on labs, cancer type, and risk—plus avoid unnecessary therapies. #IntegrativeOncology #CancerCare #SmartMedicine

Dr Bill Nelson and Dr Mike Carducci examine the latest hormone target therapies for prostate cancer, their side effect profiles and the evolution of individualized treatments.

Cancer treatments have changed dramatically over the past decade, but have our dose-finding strategies kept pace? In this episode, I speak with Dr. Ayon Mukherjee, who leads statistical innovation in early oncology development at Eli Lilly. Together, we explore Project Optimus, the FDA initiative that is changing how we think about dose optimization in oncology. Instead of simply finding the highest dose patients can tolerate, Project Optimus encourages us to identify the dose that provides the best balance between efficacy, safety, pharmacokinetics, pharmacodynamics, and long-term tolerability. Ayon explains why the traditional maximum tolerated dose approach worked well for chemotherapy but often falls short for targeted therapies and immunotherapies. We also discuss how statisticians can help lead this transformation by designing better dose optimization studies and collaborating more effectively with clinicians, pharmacologists, and regulators.

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/precision-in-practicebringing-targeted-therapy-to-mhspc/57201/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Jason Sonners is a chiropractor specializing in functional medicine. He holds a Phd in molecular biology with focus in regenerative medicine. Jason owns and operates 2 clinics with his wife Melissa in the North East. He lives in mMiami, with Melissa and 3 kids, mostly teaching lecturing and consulting for other businesses. In this episode, Dr. Jason Sonners joins Tara to unpack how the health optimization world's obsession with stacking supplements, peptides, cold plunges, and biohacking gadgets can backfire without understanding hormesis, foundational health pillars, and when targeted therapies actually make sense. RESOURCES: Learn more about Jason here: http://hbotusa.com Instagram: @hbotusa Check out Dr. Sonners books here: - Oxygen under Pressure: https://amzn.to/43OS0YM - The Art and Science of Hyperbaric Medicine: https://amzn.to/4jDGa9w Get 10% off Peluva minimalist shoe with coupon code COACHTARA here: http://peluva.com/coachtara   CHAPTERS: 0:00 – Intro 1:08 – Meet Dr. Jason Sonners 2:04 – Sponsor: Peluva Shoes Ad 3:51 – Interview Begins: Jason's PhD Journey 4:40 – What Is "Wellness Maxing"? 7:11 – Biohacking's "Be Better" Trap 11:01 – Hawaii's Low-Tech Healthy Elders 12:50 – Bryan Johnson & the Tech Age of Wellness 15:50 – Joshua Tree: Sauna in the Desert 21:00 – Introducing Hormesis 22:02 – Hormesis Explained: The Stress Bell Curve 29:46 – "Just Tell Me What to Do" Trap 31:33 – Foundational vs. Targeted Therapies 32:24 – The Peptide Craze 34:36 – Jason's 5 Foundational Health Pillars 37:01 – Next-Tier Therapies: Contrast, PEMF, Grounding 39:23 – Universal Needs vs. Your Genetics (MTHFR) 41:45 – Host Segment: Coaching, App & Retreats 46:41 – PEMF and Sound as Health Inputs 51:39 – Exercise Variety & Periodization 55:01 – What Worries Jason About Biohacking 57:16 – 3 Sources of Stress: Chemical, Physical, Emotional 1:00:38 – Success Stories: Longevity & Dementia WORK WITH TARA: Are You Looking for Help on Your Wellness Journey? Here's how Tara can help you: TRY TARA'S APP FOR FREE: http://taragarrison.com/app INDIVIDUAL ONLINE COACHING: https://www.taragarrison.com/work-with-me CHECK OUT HIGHER RETREATS: https://www.taragarrison.com/retreats   SOCIAL MEDIA:  Instagram @coachtaragarrison TikTok @coachtaragarrison Facebook @coachtaragarrison Pinterest @coachtaragarrison   INSIDE OUT HEALTH PODCAST SPECIAL OFFERS: ☑️ Upgraded Formulas Hair Test Kit Special Offer: https://bit.ly/3YdMn4Z ☑️ Upgraded Formulas - Get 15% OFF Everything with Coupon Code INSIDEOUT15: https://upgradedformulas.com/INSIDEOUT15 ☑️ Rep Provisions: Vote for the future of food with your dollar! And enjoy a 15% discount while you're at it with Coupon Code COACHTARA: https://bit.ly/3dD4ZSv   If you loved this episode, please leave a review! Here's how to do it on Apple Podcasts: Go to Inside Out Health Podcast page: https://podcasts.apple.com/us/podcast/inside-out-health-with-coach-tara-garrison/id1468368093 Scroll down to the 'Ratings & Reviews' section. Tap 'Write a Review' (you may be prompted to log in with your Apple ID). Thank you!

Highlights from the PER® CME activity "Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Justin Gainor, MD; Julia Rotow, MD; and Urs Weber, MD; discuss targeted therapies and immunotherapy to treat advanced non-small cell lung cancer (NSCLC).Earn CME credit by completing the full accredited activity (available through June 29, 2027): https://www.gotoper.com/courses/tumor-board-optimizing-nsclc-careleveraging-the-latest-evidence-on-targeted-therapy-and-immuno-oncology-1fgrThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from BioNTech; Iovance Biotherapeutics, Inc; Lilly; Nuvation Bio; Revolution Medicines, Inc; and Rigel Pharmaceuticals.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Treatment options for patients with multiple myeloma are rapidly evolving. In this podcast episode, Jesus Berdeja, MD, and Amrita Krishnan, MD, FCAP, discuss GPRC5D-directed treatment options for patients with relapsed/refractory multiple myeloma, with a focus on talquetamab, a GPRC5D-directed bispecific antibody. Topic areas covered include: Clinical trial updates and discussion of how findings may translate into clinical practice and FDA approvals Treatment sequencing and patient selection Step-up dosing and what to expect in terms of toxicity management when using a GPRC5D-targeted therapy with on-target, off-tumor effects Presenters: Jesus Berdeja, MD Director of Myeloma Research Greco-Hainsworth Centers for Research  Partner Tennessee Oncology Nashville, Tennessee Amrita Krishnan, MD, FCAP Nason Hollingworth Family Chair in Myeloma Director, Judy and Bernard Briskin Center for Myeloma Professor Hematology/HCT Executive Director of Hematology City of Hope Orange County Irvine, California Content based on an online CME program supported by an educational grant from Johnson & Johnson. Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

CME credits: 0.25 Valid until: 13-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-outcomes-in-patients-with-fsgs-a-case-based-approach-in-the-new-era-of-targeted-therapy/35906/ Focal segmental glomerulosclerosis (FSGS) remains a challenging disease, with many patients progressing to kidney failure and experiencing substantial effects on quality of life. As the treatment landscape evolves, clinicians must understand how emerging therapies may influence disease management and patient outcomes.Join Drs. Jörg Latus and Sayna Norouzi as they review the latest evidence in FSGS, including clinical data supporting the use of sparsentan in adult and pediatric patients aged 8 years and older with FSGS without nephrotic syndrome. The faculty will explore practical considerations for treatment selection, monitoring, and long-term disease management.=

Please visit answersincme.com/REE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Adam Friedman, MD. In this activity, an expert in the management of chronic spontaneous urticaria (CSU) discusses how targeted therapies fit within evolving treatment algorithms and how to integrate them appropriately into clinical practice for improved patient outcomes. Upon completion of this activity, participants should be better able to: Evaluate the rationale for targeted therapies in patients with CSU; Outline the different pathogenic mechanisms in CSU, with a focus on their relationship to type 2 inflammation, and the clinical implications of these different pathways; and Design treatment plans that optimize the use of targeted therapies in CSU, based on the latest evidence and expert insights.

Send us Fan MailThere are very few cures for cancers that have already spread. So what does a good outcome actually look like?In this clip from our episode “How Targeted Radiotherapy Is Changing Cancer Care”, host David E. Williams and John Babich, Founder, President, and Chief Scientific Officer of Ratio Therapeutics, break down what extending life with quality really means in cancer care, and why giving someone eight more months where they can still live their life is the philosophy driving the work at Ratio Therapeutics.Listen to the full episode here

Send us Fan MailFor decades, cancer treatment has rested on three pillars: surgery, chemotherapy, and external beam radiation. A fourth is now taking shape, and it is drawing billions in investment from some of the largest pharmaceutical companies in the world.John Babich, Founder, President, and Chief Scientific Officer of Ratio Therapeutics, joins host David E. Williams to explain how targeted radiotherapeutics pair a tumor-seeking molecule with a radioactive payload, delivering radiation to cancer cells while sparing healthy tissue. He also unpacks what Pluvicto's success in prostate cancer signals for the future of radioligand therapy.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TWT865. CME/EBAC/NCPD/AAPA/IPCE credit will be available until June 7, 2027.Traveling Along the TROP2-Targeted Therapy Pathway in NSCLC: Exploring the Established Role and Expanding Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TWT865. CME/EBAC/NCPD/AAPA/IPCE credit will be available until June 7, 2027.Traveling Along the TROP2-Targeted Therapy Pathway in NSCLC: Exploring the Established Role and Expanding Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TWT865. CME/EBAC/NCPD/AAPA/IPCE credit will be available until June 7, 2027.Traveling Along the TROP2-Targeted Therapy Pathway in NSCLC: Exploring the Established Role and Expanding Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TWT865. CME/EBAC/NCPD/AAPA/IPCE credit will be available until June 7, 2027.Traveling Along the TROP2-Targeted Therapy Pathway in NSCLC: Exploring the Established Role and Expanding Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

How Targeted Therapies Are Reshaping Treatment for Platinum-Resistant Ovarian Cancer Platinum-resistant ovarian cancer remains one of the most challenging settings in oncology, with limited treatment options and historically poor outcomes for many patients. On this episode of Unscripted, the AMCP Podcast, guest host Abby Kim, PharmD, BCOP, Senior Director of Clinical Strategy and Oncology Specialty Solutions at Prime Therapeutics, sits down with Kathleen Moore, MD, Deputy Director of the Fred & Pamela Buffett Cancer Center and Professor of Obstetrics and Gynecology at Nebraska Medicine, to discuss the evolving treatment landscape for recurrent ovarian cancer and the growing role of biomarker-driven care. Dr. Moore explores the history and challenges of treating platinum-resistant disease, reviews the clinical evidence behind ELAHERE®, examines the importance of folate receptor alpha testing, and shares insights on treatment sequencing, patient-reported outcomes, safety and tolerability considerations, and emerging therapies that may further expand options for patients and inform decision-making across managed care. Sponsored by Abbvie, Inc. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Featuring perspectives from Dr Lyudmila Bazhenova and Dr Corey J Langer, including the following topics: Introduction (0:00) Therapeutic Approaches Targeting HER2 and RET — Dr Bazhenova (9:09) Therapeutic Approaches Targeting ALK and ROS1 — Dr Langer (31:56) CME information and select publications

Please visit answersincme.com/860/2026-MC-001755-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Linda Stein Gold, MD and Stephan Weidinger, MD, PhD. In this activity, experts in dermatology discuss the rationale and emerging clinical data supporting the use of OX40/OX40L inhibitors for the treatment of moderate to severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting the OX40/OX40L pathway to achieve durable response in the treatment of moderate to severe atopic dermatitis (AD); Review the evidence on efficacy outcomes and safety profiles of the emerging OX40/OX40L inhibitors in AD management, including quality of life (QoL) impact; and Integrate QoL assessments into shared decision-making with patients who have moderate to severe AD.

Listen in to learn from Cristina Saura Manich, MD, PhD and Giampaolo Bianchini, MD about practical approaches to PI3K pathway testing, PI3K/AKT-targeted treatment options, and endocrine-based sequencing in metastatic breast cancer. Presenters: Cristina Saura Manich, MD, PhD Head, Breast Cancer Unit Medical Oncology Service Vall d'Hebron University Hospital Breast Cancer Program, Vall d'Hebron Institute of Oncology (VHIO) Barcelona, Spain Giampaolo Bianchini, MD Associate Professor, Universita Vita-Salute San Raffaele Head, Breast Cancer Group, Department of Medical Oncology Head, Clinical Translational and Immunotherapy Research IRCCS Ospedale San Raffaele Milan, Italy Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Visit the program page for more content associated with this discussion.https://bit.ly/4p6W8gP Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Multiple myeloma is the second most common blood cancer in the United States and has long been considered a difficult disease to treat. For decades, treatment options were limited, and survival remained poor. However, the therapeutic landscape has changed dramatically over the past several decades with the introduction of stem cell transplantation, targeted drugs, immunotherapies, and more recently, CAR T-cell therapy and bispecific antibodies. A research paper titled “Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis from 1975 to 2023” was published in Volume 17 of Oncotarget. In this study, the researchers examined how these major treatment advances have coincided with changes in multiple myeloma mortality across the United States over nearly five decades. The study was led by first and corresponding author Navkirat Kahlon from the Mass General Cancer Center at Wentworth-Douglass Hospital in Dover, New Hampshire. Full blog - https://www.oncotarget.org/2026/06/29/targeted-therapies-have-coincided-with-a-dramatic-decline-in-multiple-myeloma-mortality-in-the-united-states/ Paper DOI - https://doi.org/10.18632/oncotarget.28877 Correspondence to - Navkirat Kahlon - nkahlon@mgb.org; (ORCID: https://orcid.org/0000-0003-1115-2029) Abstract video - https://www.youtube.com/watch?v=-TNWkG9FyUo Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28877 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, multiple myeloma, epidemiologic trends, mortality reduction, therapeutic advancements, SEER database To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

#thismorning | From #Vaccines to Targeted #Therapy: The Future of #Cancer #Care | Christina Annunziata, MD, PhD, American Cancer Society | #Tunein: broadcastretirementnetwork.com #Aging, #Finance, #Lifestyle, #Privacy, #Retirement, #wellness

In this podcast, experts Manmeet Ahluwalia, MD, MBA; and Ashley S. Margol, MD, MS; discuss targeted therapies for adult and pediatric low-grade gliomas, pediatric diffuse midline glioma, and adult glioblastoma.

In this Part 1 of 2 ASCO 2026 Highlights episodes, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Alice Shaw and Dr. Jonathan Goldman to review some of the most impactful targeted therapy data presented at the 2026 ASCO Annual Meeting. The discussion explores the practice-changing LIBRETTO-432 trial in early-stage RET-positive NSCLC, long-term outcomes with lorlatinib in ALK-positive disease, emerging data for neladalkib, and promising results for sunvozertinib in EGFR exon 20 insertion–positive NSCLC, highlighting how these findings may influence treatment decisions across disease stages. Guests: Dr. Alice Shaw. is a Professor of Medicine at Harvard Medical School, Chair of Medical Oncology, and a thoracic oncologist at Dana Farber Cancer Institute. She is widely recognized as a pioneer in the field of ALK-positive non-small cell lung cancer, having led landmark clinical trials that established crizotinib, ceritinib, and lorlatinib as standards of care. Dr. Jonathan W. Goldman is a Professor of Medicine and thoracic oncologist at the UCLA David Geffen School of Medicine, where he serves as a principal investigator in the Phase I drug development program. Dr. Goldman has been at the forefront of early-phase oncology trials across multiple tumor types, with a particular focus on novel therapeutics in lung cancer, and he was the presenting author of Libretto 432 at the plenary session at the 2026 ASCO

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Jonathan Chou discusses targeted therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41563]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Jonathan Chou discusses targeted therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41563]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Jonathan Chou discusses targeted therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41563]

In this episode of Onc Now, Paolo Bironzo joins us to discuss the evolving landscape of thoracic oncology and the innovations transforming lung cancer care. From targeted therapies and immunotherapy selection to advances in mesothelioma treatment and molecular profiling, Bironzo shares insights into the challenges clinicians face today and the future of precision medicine. He also reflects on the importance of treatment de-escalation, the complexities of clinical trials, and offers advice for the next generation of oncologists. Timestamps:   00:00 – Introduction   00:51 – Inspiration Behind Thoracic Oncology   03:17 – Current Challenges in Lung Cancer   04:50 – Impact of Targeted Therapies   07:14 – Selecting Patients for Immunotherapy   08:04 – Advances in Mesothelioma Treatment   14:52 – Molecular Profiling in Thoracic Cancer   19:52 – Challenges in Lung Cancer Trials   22:05 – Predicting Immunotherapy Response Challenges   24:23 – Future of Precision Medicine   26:05 – Advice for Early-Career Oncologists   28:40 – Three Wishes for Cancer Therapy 

Only one in three eligible lung cancer patients receives the targeted therapy they should get.That is not a failure of science.It is a failure of delivery.After more than two decades of precision oncology, biopharma has never had better tools: cell and gene therapy, in vivo CAR-T, antibody-drug conjugates, AI-enabled diagnostics, organoids, multi-omics, and global clinical data.Yet too many breakthroughs still fail to reach the bedside.Patients fall through fragmented systems.Data does not move cleanly.Community oncologists are overloaded.Tests are missed, delayed, or misread.Promising assets die in quarterly portfolio reviews.And healthcare systems built for pills, tablets, and chronic disease management are now being asked to deliver personalized medicine at scale.In this SPARK20 highlight episode, Alasdair Milton, PhD, Principal at KPMG and leader of the firm's Precision & Advanced Therapies practice, explains why the future of biopharma will not be decided by science alone.It will be decided by translation.From lab bench to boardroom.From data to decisions.From treatment to prevention.Alasdair brings more than 20 years of experience across life sciences strategy, commercial due diligence, precision medicine, advanced therapies, cell and gene therapy, biopharma M&A, diagnostics, and global healthcare transformation.This conversation moves from the precision medicine delivery crisis to China's biotech acceleration, from AI and organoids to trapped pharma assets, from lifelong wellness to the one skill every future biotech leader needs:The ability to translate complex science into business strategy, capital allocation, and patient impact.What You'll Learn in 22 MinutesWhy only one third of eligible lung cancer patients receive targeted therapy(00:01:53)And why precision medicine still breaks in everyday clinical practice.Why science keeps compounding even when systems fail(00:04:33)Including in vivo CAR-T, functional cures, gene therapy, and antibody-drug conjugates.Why innovation does not move in a straight line(00:05:20)How technologies can look dead for years before suddenly changing the market.Why China's biotech speed matters(00:07:36)How AI, organoids, scale, and execution are changing the global innovation map.Why great science dies inside Big Pharma(00:09:20)And how deprioritized assets can become billion-dollar companies when externalized properly.Why the industry must move from sickness to lifelong wellness(00:10:03)Alasdair's vision for a more proactive, preventive, data-driven healthcare system.Why pharma needs better ways to rescue shelved assets(00:13:06)Including examples such as SpringWorks, Cerevel, and new models for unlocking trapped value.How a 400-person Scottish island shaped Alasdair's worldview(00:15:07)The personal story behind his resilience, discipline, and leadership style.Why careers and companies are never linear(00:17:19)What Alasdair learned after moving to Boston and losing his role within weeks.Why the future belongs to translators(00:20:06)The most valuable skill in biotech: explaining complex science to business leaders, investors, and boards.How to connect with Alasdair Milton and the KPMG Precision & Advanced Therapies team(00:21:47)Quotes to Carry With You

Drs. Mantia and Berg continue their discussion of ESMO 2025 data on HER2‑directed antibody–drug conjugates in urothelial cancer and the importance of routine HER2 testing. They highlight the promising efficacy and manageable toxicity of these agents across disease stages and raise future questions about how best to sequence them.

Featuring proceedings from a live event on January 9, 2026, held adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium and moderated by Dr Samuel J Klempner, including the following topics: Treatment approach for metastatic HER2-negative, claudin 18.2-positive, microsatellite instability-high gastroesophageal (GE) cancer (0:00) Duration of chemotherapy for patients with advanced GE cancers receiving nivolumab/chemotherapy (3:06) Younger patient with metastatic PD-L1-positive gastric cancer (5:29) CME information and select publications

Pediatric thyroid nodules are rare, but their risk of malignancy is significantly higher than in adults, raising the stakes for accurate diagnosis and multidisciplinary management. In this episode of the BackTable ENT Podcast Dr. Gopi Shah and co-host Dr. Jeff Hyzer interview Dr. Wen Jiang, pediatric otolaryngologist at Rady Children's Hospital in San Diego, for an in-depth discussion on the evaluation and management of thyroid nodules in children. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction 02:27 - Thyroid Nodule Risks and Care Team 06:47 - Age-related Differences in Nodule Presentation and Outcomes08:50 - Initial workup 13:42 - Ultrasound Interpretation16:07 - Lymph Node Mapping and CT19:58 - Incidental Findings24:14 - Role of FNA, Molecular Testing, and Radiofrequency Ablation32:40 - Molecular Testing Results and Counseling 38:04 - Neck Dissection Strategy40:44 - Hypocalcemia Protocol Considerations44:01 - Parathyroid and Recurrent Laryngeal Nerve Dissection Tips 47:33 - Postop Care and Follow-up 51:25 - Using Radioactive Iodine and Targeted Therapy 54:55 - AI's and Ultrasound and Final Thoughts --- More about this episode Dr. Jiang highlights the key differences between pediatric and adult thyroid nodules. She describes her multidisciplinary approach including collaboration with radiology, pathology, endocrinology and nuclear medicine. The discussion reviews the initial workup for pediatric thyroid nodules and why ultrasound remains the primary diagnostic tool. She also discusses situations where CT with contrast can be helpful for surgical planning. This episode explores the growing role of reflex molecular testing in guiding management decisions and outlines the impacts of molecular testing results. Dr. Jiang shares her approach to patient counseling along with management of calcium and PTH after surgery. The conversation concludes with emerging applications of molecular diagnostics and AI models for improving thyroid ultrasound interpretation. --- Resources Dr. Jiang's Research on Pediatric Thyroid Nodule Management - https://pubmed.ncbi.nlm.nih.gov/26770219/ Bethesda System for Thyroid Cytopathology - https://pmc.ncbi.nlm.nih.gov/articles/PMC7182964/ --- BackTable ENT & Allergy is the go-to podcast for otolaryngologists, allergists, and head and neck surgeons. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

We're going to cure cancer in our lifetime." It's a rallying cry at every charity event, every fundraiser, every race. But what does that actually mean?Dr. Sonal Gandhi, a medical oncologist, joins Ditch the Labcoat to break down what most people don't understand: we already cure cancer. All the time. Early stage cancers like breast, colon, and skin cancer caught in time have cure rates approaching 90 to 100 percent.The challenge is stage four cancer. Metastatic disease. Cancer that has spread to other organs. And even there, the conversation is shifting. Cancer is increasingly becoming a chronic illness. People are living longer with it, sometimes dying with it rather than from it, just like they do with heart disease or diabetes.Dr. Gandhi walks through what "curing cancer" really means, how treatment has evolved beyond chemotherapy into targeted therapies and immunotherapy, and why prevention matters. Up to 40 percent of cancers are related to modifiable lifestyle factors: smoking, alcohol, obesity, lack of exercise. But even doing everything right doesn't guarantee you won't get cancer. Age is the number one risk factor, and we can't modify that.She also challenges the guilt people carry when they're diagnosed and reframes the fear around the "C word." Maybe it's time to pull cancer back into the middle with the menu of other chronic illnesses we manage, not cure.If you've ever wondered what "curing cancer" actually means, why some cancers are more treatable than others, or what you can do to reduce your risk, this episode will reframe how you think about one of medicine's most feared diagnoses.If you've ever wondered why so many people have unexplained symptoms, why standard treatments fail them, or what actually works when medicine runs out of answers, this episode will reframe how you see chronic illness.Dr. Sonal Gandhi's LinkedinEpisode Takeaways1. We already cure cancer. Early stage cancers (stage 1 or 2) caught in time have cure rates approaching 90 to 100 percent, depending on the type.2. Cancer is not one disease. It's dozens of diseases with different stages, treatments, and outcomes. We're better at treating some than others.3. Stage four (metastatic) cancer is increasingly becoming a chronic illness. Treatments help people live longer with cancer, sometimes dying with it rather than from it.4. Up to 40 percent of cancers are related to modifiable lifestyle factors: smoking, alcohol, obesity, and lack of exercise. Being a healthy weight matters for cancer prevention.5. Age is the number one risk factor for cancer. Every decade you get older, cells get worse at repairing mistakes. We can't modify aging.6. Only 10 to 20 percent of cancers are due to inherited genes. Most cancers happen because of the complicated interplay between lifestyle, environment, and cellular aging.7. Immunotherapy works by preventing cancer cells from turning off the immune system, but it can cause severe autoimmune side effects that need rapid treatment.8. Whole body scans and experimental blood tests sound appealing, but they often create more harm than good. Screening needs to be done in context with clear downstream action plans.Episode Timestamps03:51 – What Does "Curing Cancer" Actually Mean?08:15 – Early Stage vs. Late Stage Cancer: The Critical Difference12:42 – How Chemotherapy, Targeted Therapy, and Immunotherapy Work18:35 – Prevention: Lifestyle Factors That Reduce Cancer Risk21:50 – Why Immunotherapy Can Cause Severe Side Effects30:48 – Cancer as a Chronic Illness, Not a Death Sentence38:22 – Environmental and Occupational Cancer Risks45:51 – Why Whole Body Scans Aren't the AnswerDISCLAMER >>>>>>    The Ditch Lab Coat podcast serves solely for general informational purposes and does not serve as a substitute for professional medical services such as medicine or nursing. It does not establish a doctor/patient relationship, and the use of information from the podcast or linked materials is at the user's own risk. The content does not aim to replace professional medical advice, diagnosis, or treatment, and users should promptly seek guidance from healthcare professionals for any medical conditions.   >>>>>> The expressed opinions belong solely to the hosts and guests, and they do not necessarily reflect the views or opinions of the Hospitals, Clinics, Universities, or any other organization associated with the host or guests.    Disclosures: Ditch The Lab Coat podcast is produced by (soundsdebatable.com) and is independent of Dr. Bonta's teaching and research roles at McMaster University, Temerty Faculty of Medicine and Queens University.

Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Role of PD-L1 status, tumor histology and pulmonary disease in selection of immune checkpoint inhibition as up-front therapy (0:00) Impact of metastatic site and autoimmune disease on clinical decision-making in the use of immune checkpoint inhibition (5:56) Biomarker assessment approach and treatment selection (10:50) CME information and select publications